Current developments in pediatric systemic sclerosis

被引:2
|
作者
Foeldvari I. [1 ]
机构
[1] Hamburger Zentrum für Kinder- und Jugendrheumatologie, Kompetenz-Zentrum für Sklerodermie und Autoimmune Uveitis im Kindesalter, Am Klinikum Eilbek, Hamburg D-22081
关键词
Systemic Sclerosis; Organ Involvement; Calcinosis; Mixed Connective Tissue Disease; Skin Score;
D O I
10.1007/s11926-009-0014-4
中图分类号
学科分类号
摘要
Juvenile systemic sclerosis is an orphan disease with an incidence of around 0.05 per 100,000 children. The mean age of onset is approximately 8 years, and 90% of pediatric patients have a diffuse subset. The organ involvement of pediatric patients differs from adult patients. Survival rates are significantly better in pediatric patients than in adult patients. Most patients who die in the first 5 years of the disease have a diffuse subset. Interestingly, the disease subset shifts when pediatric patients are reviewed in adult cohorts of systemic sclerosis patients, in which only around 40% of patients have diffuse subset. The pediatric-onset patients still have a low prevalence of anticentromere antibodies. There is a larger group of patients with overlap features in juvenile systemic sclerosis than in adult cohorts. There are also noticeable differences in organ involvement. © 2009 Current Medicine Group, LLC.
引用
收藏
页码:97 / 102
页数:5
相关论文
共 50 条
  • [41] Current Therapeutic Options in Pediatric Multiple Sclerosis
    E. Ann Yeh
    Current Treatment Options in Neurology, 2011, 13 : 544 - 559
  • [42] Current Therapeutic Options in Pediatric Multiple Sclerosis
    Yeh, E. Ann
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2011, 13 (06) : 544 - 559
  • [43] Current Advances in Pediatric Onset Multiple Sclerosis
    Fisher, Kristen S.
    Cuascut, Fernando X.
    Rivera, Victor M.
    Hutton, George J.
    BIOMEDICINES, 2020, 8 (04)
  • [44] Current developments in MRI for assessing rodent models of multiple sclerosis
    Alomair, Othman I.
    Smith, Maree T.
    Brereton, Ian M.
    Galloway, Graham J.
    Kurniawan, Nyoman D.
    FUTURE NEUROLOGY, 2014, 9 (04) : 487 - 511
  • [45] Treatment of digital ulcers in systemic sclerosis: recent developments and future perspectives
    Ioannis Sagonas
    Dimitrios Daoussis
    Clinical Rheumatology, 2023, 42 : 2589 - 2599
  • [46] Treatment of digital ulcers in systemic sclerosis: recent developments and future perspectives
    Sagonas, Ioannis
    Daoussis, Dimitrios
    CLINICAL RHEUMATOLOGY, 2023, 42 (10) : 2589 - 2599
  • [47] Pathogenesis of systemic sclerosis—current concept and emerging treatments
    Masutaka Furue
    Chikage Mitoma
    Hiroki Mitoma
    Gaku Tsuji
    Takahito Chiba
    Takeshi Nakahara
    Hiroshi Uchi
    Takafumi Kadono
    Immunologic Research, 2017, 65 : 790 - 797
  • [48] CURRENT AND NEW APPROACHES TO THE TREATMENT OF SYSTEMIC-SCLEROSIS
    ZANUSSI, C
    SMERALDI, RS
    EOS-RIVISTA DI IMMUNOLOGIA ED IMMUNOFARMACOLOGIA, 1992, 12 (03): : 201 - 205
  • [49] Pathophysiology of systemic sclerosis: current understanding and new insights
    Cutolo, Maurizio
    Soldano, Stefano
    Smith, Vanessa
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (07) : 753 - 764
  • [50] Heterogeneity of Autoantibodies in Systemic Sclerosis: Reconsidering Current Paradigms
    Mehra, Sonal
    Baron, Murray
    Stephenson, Mat
    Hudson, Marie
    Pope, Janet E.
    Fritzler, Marvin J.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S631 - S631